Welcome to our dedicated page for Rigel Pharmaceuticals SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals鈥� SEC documents can stretch well past 200 pages, packed with clinical-trial data tables, milestone accounting, and detailed R&D spend. Finding the nuggets that move RIGL鈥檚 share price鈥攕uch as SYK inhibitor trial updates or cash-runway projections鈥攖akes time investors rarely have.
Stock Titan鈥檚 AI-powered analysis turns those dense reports into clear insights. As soon as a Rigel Pharmaceuticals quarterly earnings report 10-Q filing or an 8-K on pivotal study results hits EDGAR, our engine surfaces key metrics, explains them simply, and links to prior disclosures for context. Want to track Rigel Pharmaceuticals insider trading Form 4 transactions in real time? We alert you the moment executives buy or sell, highlighting patterns around FDA or partnership announcements.
Every filing type is covered and explained:
- 10-K annual report: cash position, pipeline outlook, risk factors鈥�Rigel Pharmaceuticals annual report 10-K simplified.
- 10-Q: quarter-over-quarter R&D spend and collaboration revenue, with AI charts.
- Form 4: Rigel Pharmaceuticals executive stock transactions Form 4 flagged instantly.
- 8-K: trial readouts or licensing deals鈥�Rigel Pharmaceuticals 8-K material events explained.
- DEF 14A proxy: Rigel Pharmaceuticals proxy statement executive compensation summarized in plain English.
Use the platform to compare segment costs, monitor Rigel Pharmaceuticals Form 4 insider transactions real-time, or quickly answer, 鈥淗ow do I understand Rigel Pharmaceuticals SEC documents with AI?鈥� No more scrolling through footnotes鈥攋ust the information that informs your next move.
Armistice Capital, LLC and Steven Boyd filed a Schedule 13G/A reporting beneficial ownership of 1,600,000 shares of Rigel Pharmaceuticals, representing 8.92% of the outstanding common stock. The filing states these shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital serves as investment manager and over which Armistice Capital and Mr. Boyd share voting and dispositive power.
The filing clarifies the Master Fund retains the economic right to proceeds or dividends while disclaiming direct beneficial ownership due to the investment management agreement. All reported share counts are based on 17,937,340 shares outstanding as of July 31, 2025, per the issuers SEC filing.
On 6 Aug 2025, Rigel Pharmaceuticals (RIGL) filed a routine Form S-8 to register 825,000 additional common shares for employee equity compensation: 125,000 shares under the Inducement Plan and 700,000 shares under the 2018 Equity Incentive Plan. The filing incorporates prior S-8s by reference and includes the usual legal opinions, consents and power-of-attorney exhibits; it contains no new earnings, balance-sheet data or corporate actions beyond the share registration. The statement ensures Rigel has sufficient shares available for future option and restricted-stock grants, supporting talent recruitment and retention. While the registration itself does not raise capital, any subsequent issuance of the shares will incrementally dilute existing shareholders.
FAQ
What is the current stock price of Rigel Pharmaceuticals (RIGL)?
What is the market cap of Rigel Pharmaceuticals (RIGL)?
